School of Medicine
Showing 1-8 of 8 Results
-
Paul M. Maggio, MD, MBA, FACS
Clinical Professor, Surgery - General Surgery
BioDr. Paul Maggio is a Professor of Surgery, Chief Quality Officer for Stanford Health Care, and Associate Dean for Quality and Clinical Affairs in the Stanford School of Medicine. He trained in General Surgery at Brown University and obtained advanced training in Adult Surgical Critical Care and Trauma at the University of Michigan. He holds a Master of Business Administration from the University of Michigan and is triple board certified in General Surgery, Critical Care, and Medical Informatics. His clinical focus is on Acute Care Surgery and Critical Care Medicine, and his academic career has been centered on quality improvement, patient safety, and the application of systems engineering to enhance the delivery of healthcare.
Dr. Maggio participates in the National Committee on Healthcare Engineering for the American College of Surgeons and has served on the Baldrige Board of Examiners to recognize organizations with the highest presidential honor for performance excellence. Dr. Maggio received the SHC Board of Hospital Director’s Denise O’Leary Award for Clinical Excellence in 2013 -
Vanni Manthiram
Clinical Assistant Professor (Affiliated), Surgery - General Surgery
BioDr. Vanni Manthiram is board certified in General Surgery. She practices a broad range of general surgery including breast, colon, gall bladder, hernia, and minimally invasive surgery.
She is also a member of several professional organizations, including the American College of Surgeons and the American Society of Breast Surgeons.
Dr. Manthiram became a surgeon because it is extremely rewarding as patients are very grateful and often feel better immediately. She also enjoys making sure her patients understand the planned procedure.
Her personal interests include watching football, hiking, fitness, and spending time with family. -
Arden Morris, MD, MPH, FACS
Robert L. and Mary Ellenburg Professor of Surgery, and Professor, by courtesy, of Health Policy
BioArden M. Morris, MD, MPH is Vice-Chair for Clinical Research, the Robert L. and Mary Ellenburg Professor of Surgery, and by courtesy Professor of Health Policy at the Stanford School of Medicine. She is Director of the S-SPIRE Center, a health services research collaborative to study patient-centered care, clinical optimization, and health care economics. In her own work, Dr. Morris uses quantitative, qualitative, and mixed research methods to focus on quality of and equity in cancer care. To that end, she currently is funded by American Cancer Society and NIH to study access to care, clinical outcomes, and policy related to insurance design. Dr. Morris currently serves on the American Joint Commission on Cancer, the NIH Special Emphasis Panel “Topics in Health Services Research: Big Data, Health Information Technology, and Clinical Informatics,” and as Associate Editor for Surgery at JAMA Network Open.
-
Adel Mutahar
Postdoctoral Scholar, General and Vascular Surgery
BioDr. Adel Z. I. Mutahar is a postdoctoral researcher in the Department of Surgery at Stanford University, working under the mentorship of Dr. Frederick M. Dirbas. His research focuses on translational breast cancer biology and emerging radiotherapy technologies, with an emphasis on tumor–microenvironment interactions, immuno-oncology, and preclinical therapeutic development. His academic journey spans three countries—beginning in Yemen, advancing through India, and now progressing at Stanford—reflecting his commitment to impactful cancer research and global scientific advancement.
Dr. Mutahar began his career in Yemen, earning his Bachelor’s degree in Medical Laboratory Sciences before joining Abs Community College as a faculty member. From 2007–2013, he held several academic leadership roles, including Academic Director, Head of Evaluation, and Assistant Dean of Students, where he modernized curriculum, expanded hands-on diagnostic training, and strengthened laboratory education infrastructure in resource-limited settings. His work contributed to building a more skilled medical diagnostics workforce and improving pathways for laboratory science education.
Awarded a prestigious national merit scholarship, Dr. Mutahar continued his graduate and doctoral training in India, completing his M.S. and Ph.D. in Biotechnology with a focus on triple-negative breast cancer. During his doctoral work, he developed 3D tumor spheroid models and combinatorial therapeutic strategies, demonstrating synergy between anti-angiogenic agents and chemotherapy in TNBC. He further advanced this research by creating an orthotopic murine model to investigate metastatic progression and demonstrated that knockdown of the MTA1 gene in mesenchymal stem cells (MSCs) significantly suppressed TNBC invasion, angiogenesis, and metastatic spread, introducing a promising stromal-targeted therapeutic concept for aggressive breast cancer. This work earned recognition through travel grants, conference presentations, and a Best Poster Award. His scientific adaptability was further demonstrated during the COVID-19 pandemic, when he uncovered a novel interaction between SARS-CoV-2 Spike RBD and VEGF signaling.
At Stanford, his work emphases on FLASH radiotherapy, an ultrahigh-dose-rate modality with the potential to widen the therapeutic window by minimizing normal-tissue toxicity while maintaining tumor control. Working within Dr. Dirbas’s translational breast oncology program, Dr. Mutahar employs patient-derived xenografts, orthotopic murine models, spatial transcriptomics, single-cell RNA sequencing, and immune profiling to dissect the biological mechanisms governing treatment response. His research integrates multi-omics analysis to map early and late radiotherapy injury pathways—including senescence, apoptosis and fibrosis. His goal is to develop mechanism-driven radio-immunotherapy strategies and durable FLASH-RT combination regimens that can be translated into clinical trials for breast cancer, improving therapeutic durability, minimizing toxicity, and ultimately enhancing patient outcomes.
Dr. Mutahar’s long-term vision is to establish an independent laboratory at the intersection of radiobiology, immuno-oncology, and translational therapeutics. Guided by Dr. Dirbas’s mentorship and shaped by multidisciplinary experience across three continents, he aims to develop biologically informed treatment strategies that eradicate tumors while preserving normal tissue and immune integrity—ultimately improving quality of life and survival for women with aggressive breast cancers.
